推荐产品
化驗
99.9%
製造商／商標名
Goodfellow 609-486-58
電阻係數
7.1 μΩ-cm, 0°C
bp
3900 °C (lit.)
mp
2310 °C (lit.)
密度
12.45 g/cm3 (lit.)
SMILES 字串
[Ru]
InChI
1S/Ru
InChI 密鑰
KJTLSVCANCCWHF-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般說明
For updated SDS information please visit www.goodfellow.com.
法律資訊
Product of Goodfellow
儲存類別代碼
13 - Non Combustible Solids
水污染物質分類（WGK）
nwg
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Nicole L Fry et al.
Accounts of chemical research, 44(4), 289-298 (2011-03-03)
Nitric oxide (NO) can induce apoptosis (programmed cell death) at micromolar or higher doses. Although cell death via NO-induced apoptosis has been studied quite extensively, the targeted delivery of such doses of NO to infected or malignant tissues has not
Lutz Ackermann et al.
Topics in current chemistry, 292, 211-229 (2010-01-01)
Stoichiometric cycloruthenation reactions of substrates containing Lewis-basic functionalities set the stage for efficient ruthenium-catalyzed C-H bond functionalization reactions. Thereby, selective addition reactions of C-H bonds across alkenes or alkynes enabled atom-economical synthesis of substituted arenes. More recently, ruthenium-catalyzed direct arylation
Christian G Hartinger et al.
Current topics in medicinal chemistry, 11(21), 2688-2702 (2011-11-02)
Polynuclear compounds are a relatively new and successful approach in metal-based cancer chemotherapy as typified by the trinuclear Pt compound BBR3464 which was evaluated in clinical trials. In this review, we discuss newer developments of polynuclear ruthenium, osmium and gold
Martin R Gill et al.
Chemical Society reviews, 41(8), 3179-3192 (2012-02-09)
In the last few decades, coordination complexes based on d(6) metal centres and polypyridyl ligand architectures been developed as structure- and site-specific reversible DNA binding agents. Due to their attractive photophysical properties, much of this research has focused on complexes
A Bergamo et al.
Journal of inorganic biochemistry, 106(1), 90-99 (2011-11-25)
The study of metal complexes for the treatment of cancer diseases has resulted in the identification of some unique properties of ruthenium-based compounds. Among these inorganic-based agents, two of them, namely the ruthenium(III) drugs NAMI-A and KP1019 have undertaken with
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门